Immunome, Inc. $IMNM Shares Sold by EcoR1 Capital LLC

EcoR1 Capital LLC lowered its holdings in shares of Immunome, Inc. (NASDAQ:IMNM) by 30.0% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,855,590 shares of the company’s stock after selling 1,223,825 shares during the period. Immunome comprises about 2.8% of EcoR1 Capital LLC’s portfolio, making the stock its 8th biggest holding. EcoR1 Capital LLC owned about 2.59% of Immunome worth $61,338,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Strs Ohio acquired a new position in shares of Immunome during the 4th quarter worth $64,000. Assetmark Inc. acquired a new stake in shares of Immunome during the 3rd quarter valued at $39,000. Aster Capital Management DIFC Ltd acquired a new stake in shares of Immunome during the 4th quarter valued at $121,000. BIT Capital GmbH acquired a new position in Immunome in the 3rd quarter worth about $69,000. Finally, BNP Paribas Financial Markets increased its holdings in Immunome by 81.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock worth $60,000 after purchasing an additional 2,909 shares in the last quarter. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Stock Up 3.5%

Shares of IMNM opened at $18.53 on Thursday. Immunome, Inc. has a 12-month low of $7.96 and a 12-month high of $27.65. The business has a 50-day simple moving average of $21.56 and a two-hundred day simple moving average of $21.70. The stock has a market cap of $2.10 billion, a PE ratio of -7.79 and a beta of 2.04.

Immunome (NASDAQ:IMNM) last issued its earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.12. On average, equities research analysts expect that Immunome, Inc. will post -2.06 EPS for the current year.

Analysts Set New Price Targets

IMNM has been the subject of a number of recent research reports. Truist Financial upped their target price on Immunome from $36.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, May 28th. Wall Street Zen cut Immunome from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. Craig Hallum upped their target price on Immunome from $33.00 to $36.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. Stephens lowered their target price on Immunome from $33.00 to $30.00 and set an “overweight” rating for the company in a report on Wednesday, March 4th. Finally, Barclays initiated coverage on Immunome in a report on Thursday, May 28th. They issued an “overweight” rating and a $36.00 target price for the company. Twelve research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $33.17.

Insider Buying and Selling

In other Immunome news, CFO Max Rosett sold 60,000 shares of the company’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $18.23, for a total value of $1,093,800.00. Following the sale, the chief financial officer owned 54,037 shares in the company, valued at approximately $985,094.51. The trade was a 52.61% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jack Higgins sold 9,438 shares of the company’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $21.64, for a total value of $204,238.32. Following the completion of the sale, the insider owned 22,000 shares in the company, valued at $476,080. This trade represents a 30.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 199,438 shares of company stock worth $4,058,464. Corporate insiders own 7.21% of the company’s stock.

Immunome Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.